SLAMF1 and B-cell chronic lymphocytic leukemia: The results of Bologna et al. indicate that loss of SLAMF1/CD150 expression in CLL modulates genetic pathways that regulate autophagy and that could potentially negatively affect responses to drugs such as fludarabine or venetoclax, a BCL2 inhibitor recently approved for front-line therapy of CLL.